Younossi Zobair M, Razavi Homie, Sherman Michael, Allen Alina M, Anstee Quentin M, Cusi Kenneth, Friedman Scott L, Lawitz Eric, Lazarus Jeffrey V, Schuppan Detlef, Romero-Gómez Manuel, Schattenberg Jörn M, Vos Miriam B, Wong Vincent Wai-Sun, Ratziu Vlad, Hompesch Marcus, Sanyal Arun J, Loomba Rohit
Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
The Global NASH Council, Washington, DC, USA.
Aliment Pharmacol Ther. 2025 May;61(9):1467-1478. doi: 10.1111/apt.70020. Epub 2025 Feb 18.
The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity-linked insulin resistance, glucose homeostasis, lipid metabolism and pro-inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well-being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non-invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD-related problem.
The aim of this article was to summarise the global burden of MASLD from the payer's perspective.
We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient-reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively.
The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs.
NCT06309992.
代谢综合征的连续体包含一系列功能障碍，影响与肥胖相关的胰岛素抵抗、葡萄糖稳态、脂质代谢和促炎免疫反应。近几十年来，包括糖尿病、慢性肝病、心脏代谢疾病和肾病在内的代谢性疾病在全球的患病率激增，对人口死亡率有重大影响。代谢功能障碍相关脂肪性肝病（MASLD），以前称为非酒精性脂肪性肝病，是全球肝病的主要原因。MASLD患病率不断上升，给全球卫生带来重大挑战，给医疗系统带来沉重负担，影响患者福祉并产生巨大经济成本。应对MASLD需要全面了解其相互关联的因素，包括其患病率、医疗负担和经济影响。认识不足、非侵入性诊断方法不准确以及预防性干预措施无效是与MASLD相关问题的核心组成部分。
本文旨在从支付方的角度总结MASLD的全球负担。
我们对MASLD的全球综合负担进行了综述。这些主题引发了专家小组在2023年11月举行的第七届代谢连续体圆桌会议上的讨论和见解。本次会议从支付方和社会角度关注负担、患者报告的结果和健康经济学，旨在确定改善患者护理、优化资源分配以及减轻与MASLD相关的对个人和社会的总体影响的机会。在圆桌会议期间，人们强调需要提高认识，并战略性地部署诊断、治疗和预防措施，以有效应对MASLD。
MASLD的全球负担很高且在不断增加。优先预防代谢失调并及时进行治疗干预，可以产生一个全面的策略来对抗MASLD、其进展，并可能降低疾病成本。
NCT06309992。
